In its first meeting, a carefully chosen advisory committee of experts on gene editing under the World Health Organization this week agreed on the immediate need for a global registry of research that funders should make binding for researchers. The group acknowledged an urgency in addressing human gene editing governance in light of work already taking place, but stopped short of calling for a moratorium at this time, instead issuing a statement that it would be "irresponsible" for anyone to proceed with such research now. Continue reading ->
A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years. Continue reading ->
The United Nations late last month sought to hold landmark high-level meetings on ending tuberculosis and fighting noncommunicable diseases like cancer and cardiovascular disease, with mixed results. Now a Swiss-based expert is looking at the outcomes and what comes next, and in a webinar talked about the political trade-offs resulting from the meetings, the need to push for an integrated agenda on Universal Health Coverage, and how the private sector should be engaged. Continue reading ->
Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading ->
The 70th annual World Health Assembly (WHA), now underway in Geneva, is shaping up to be one of the most consequential in memory. With a record-setting nine-day, 76-item agenda, plus dozens of official and unofficial side events, delegates and WHO followers alike will be hard-pressed to keep up. But yesterday’s introductory briefing, hosted by the Global Health Centre at the Graduate Institute, provided an overview of the proceedings and a few pointers on where to look first. Four items, in particular, stand out. Continue reading ->